At Curaleaf Clinic, we’re dedicated to researching and sharing how eligible patients with certain medical conditions may access medical cannabis. This ensures we help healthcare professionals and patients make the right decisions for them and their conditions.
As part of this commitment, the team at Curaleaf are attending the 34th Annual International Cannabinoid Research Society (ICRS) Symposium on the Cannabinoids, taking place from June 30 – July 5, 2024, in Salamanca, Spain.
Our own Dr Simon Erridge, Research Director at Curaleaf Clinic, and Dr Mikael Sodergren, Chief Medical Officer at Curaleaf International, will be attending this event for the fourth year in a row. This conference is a platform for showcasing the latest cannabinoid research and for collaboration among the world’s leading experts in the field.
During the conference, Dr. Erridge will deliver a presentation on “Clinical Outcomes Analysis of Medical Cannabis for Chronic Cancer Pain.” This research delves into the outcomes of patients seen at Curaleaf Clinic with chronic cancer pain. He says: “With cancer affecting millions worldwide and pain being a significant problem for nearly 1 in 2 cancer patients, the findings from the UK Medical Cannabis Registry help further build the evidence on how medical cannabis can be prescribed for patients with cancer.”
These findings come from the UK Medical Cannabis Registry, a UK patient registry for cannabis-based medicinal products, set up by Curaleaf Clinic.
We would like to extend a huge thank you to all of our Curaleaf Clinic patients who contribute to the UK Medical Cannabis Registry via the Curaleaf Access Scheme. The Registry data will help shape health policy and the care they receive through the clinic, whilst we await randomised clinical trials.
To find out more about the UK Medical Cannabis Registry’s latest research and publications visit – https://ukmedicalcannabisregistry.com/
